Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau

Epigenetic remodeling via histone acetylation has become a popular therapeutic strategy to treat Alzheimer’s disease (AD). In particular, histone deacetylase (HDAC) inhibitors including M344 and SAHA have been elucidated to be new drug candidates for AD, improving cognitive abilities impaired in AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Hyeanjeong, Shin, Seulgi, Lee, Jun-Seok, Lee, Soo Hyun, Baik, Ja-Hyun, Lim, Sungsu, Kim, Yun Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747090/
https://www.ncbi.nlm.nih.gov/pubmed/31480543
http://dx.doi.org/10.3390/ijms20174283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747090/
https://www.ncbi.nlm.nih.gov/pubmed/31480543
http://dx.doi.org/10.3390/ijms20174283

Ejemplares similares